What happenedOn August 24, Judge Randolph Moss of the U.S. District Court for the District of Columbia granted intervention to the National Association of Community Health Centers, RWC-340B, and 340B Health in AbbVie Inc. v. Kennedy, No. 1:26-cv-01190, the manufacturer’s challenge to HRSA’s 340B patient definition (340B Report, Aug. 27). The three groups will join HRSA in defending the definition AbbVie calls overly broad and inconsistent with the statute. The court entered a scheduling order August 26, and the government’s reply brief on its motion to dismiss is due August 31 (Georgetown litigation tracker).

Why it mattersThe patient definition sets how much of a covered entity’s prescription volume earns 340B pricing, which makes this the highest-stakes administrative case the program currently faces. Intervention puts provider counsel in the room for any settlement discussion and preserves an appeal path independent of the government’s choices. After HHS declined to defend its first rebate pilot in February and asked the court to vacate it, the sector has reason to hold its own insurance on this docket. The same textual method that stripped eleven clinics’ certifications in the Sagebrush ruling two weeks ago is now aimed at the word “patient,” and a literal reading there would reach much further.

What happenedFroedtert Hospital sued CVS Health and its subsidiaries, including CVS Caremark, in the U.S. District Court for the Eastern District of Wisconsin, alleging the vertically integrated company improperly kept about $18 million in 340B savings that belonged to the Milwaukee system (Wisconsin Law Journal, Aug. 28). The complaint alleges CVS entities retained roughly 62 percent of savings while Froedtert received about 38 percent, and that CVS concealed the arrangement through its control of the pharmacy, PBM, and insurance layers. Froedtert is the fifth covered entity to bring such a suit, following Mount Sinai, Michigan Medicine, the University of Kansas Health System, and Henry Ford Health; the four earlier plaintiffs collectively estimate more than $277 million in losses since 2020, before Froedtert’s $18 million. CVS called the complaint “riddled with erroneous accusations” and promised a vigorous defense.

Why it mattersThe theory keeps traveling: each new complaint reuses the same structure, a covered entity auditing its own contract pharmacy and PBM remittances and pleading the shortfall as breach of contract and state law violations. Five suits on one template make this a pattern manufacturers, PBMs, and plaintiffs’ firms are all now studying, and every covered entity with CVS-family contracts holds the same records Froedtert used. The dollar figures also feed both sides of the reform debate: they document real safety-net losses while confirming how much money moves through intermediaries.

What happenedIn an August 21 ruling that reached the trade press this week, a federal judge in Mississippi granted the state summary judgment against AstraZeneca’s preemption challenge to its 340B contract pharmacy access law, dismissing the complaint with prejudice; the court held it was bound by a prior decision that the presumption against preemption applies to the Defending Affordable Prescription Drug Costs Act (340B Report, Aug. 25; Mealey’s, Aug. 26). The same week brought movement across the map: Missouri’s S.B. 878, which bars PBMs and insurers from discriminating against 340B grantee covered entities and their pharmacies, took effect August 28 (340B Report, Aug. 27), a manufacturer plaintiff moved for a preliminary injunction against Illinois’ new law, North Dakota’s appellees briefed the Eighth Circuit, and Missouri’s defenders opposed en banc review (McDermott, This Week in 340B).

Why it mattersMississippi has now beaten back challenges at the preliminary, appellate, and merits stages, and each dismissal with prejudice strengthens the template other states copy. Missouri’s new law extends shield protection to grantees and their pharmacies against PBMs, a different defendant class than the manufacturer-facing statutes, which widens what state legislatures believe they can regulate. The Illinois preliminary injunction motion is the one to watch: it will produce the first judicial read on the most heavily litigated shield law in the country.

What happenedIn back-to-back filings, the American Hospital Association told Senator Cassidy’s committee on August 25 that his 340B discussion draft would “fundamentally alter the operation of the program, impose substantial new administrative and financial burdens on hospitals,” urging Congress to preserve the upfront discount model and rework the draft’s patient and child site definitions (AHA, Aug. 25). On August 26 it told CMS not to finalize the CY2027 OPPS proposals, arguing the ASP minus 33.4 percent payment rate rests on a flawed acquisition cost survey, calling the accelerated clawback, which would rise from 0.5 percent to 3 percent a year, illegal, and urging HHS to rescind it entirely (AHA, Aug. 26). OPPS comments close August 31.

Why it mattersThe association put “serious legal defects” on the record against a live CMS proposal, which reads as a litigation predicate, not just advocacy. Hospitals have sued over 340B payment cuts before and won at the Supreme Court; a finalized minus 33.4 percent rate with a 3 percent clawback would put billions in motion on a theory AHA has already branded unlawful. The Cassidy letter matters for a different reason: with feedback closed August 28, the discussion draft now moves toward introduced text, and the sector’s asks are on the record before drafting hardens. Single-issue bills keep arriving alongside it; Rep. Hillary Scholten introduced H.R. 10134, the Local Health Care Protection Act of 2026, on August 20; it would temporarily let hospitals keep 340B eligibility when their disproportionate share percentages slip below the thresholds (H.R. 10134; 340B Report, Aug. 25).

What happenedMonday, August 24 was the deadline for selected manufacturers to submit rebate plans to HRSA under the revised 340B Rebate Model Pilot Program (Federal Register, Aug. 3). As of August 29, neither HRSA nor any manufacturer has published which plans went in; approvals are due by September 24 and the pilot takes effect January 1, 2027. Drug Channels’ August 25 analysis framed the design choice plainly: the Inflation Reduction Act created a nonduplication requirement between the Maximum Fair Price and the 340B ceiling price, upfront discounts cannot reliably determine which price applies at the transaction level, and the pilot’s roughly $5.5 billion slice of a $100 billion program is “a good opportunity for a policy experiment like a rebate model” (Drug Channels, Aug. 25).

Why it mattersThe next month decides what covered entities actually face in January. The September 24 approval list will name the participating manufacturers, the covered drugs, and any conditions HRSA imposes, converting a Federal Register abstraction into a working capital line item. The Drug Channels framing also previews the policy fight to come: if the pilot reads as MFP deduplication machinery and nothing more, HHS gains a defensible rationale that the December lawsuit’s record never had, and the sector’s second legal challenge, if one comes, gets harder.